Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)
Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%
Amgen gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Amgen's gross profit for the twelve months ending Sep 30, 2026 was $27.58B, up 15.9% year over year. For fiscal 2025 it was $24.71B, up 20.2% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $24.71B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.71B | +20.2% |
| FY2024 | Dec 31, 2024 | $20.57B | +4.2% |
| FY2023 | Dec 31, 2023 | $19.74B | -0.9% |
| FY2022 | Dec 31, 2022 | $19.92B | +2.0% |
| FY2021 | Dec 31, 2021 | $19.53B | +1.3% |
| FY2020 | Dec 31, 2020 | $19.27B | +1.4% |
| FY2019 | Dec 31, 2019 | $19.01B | -3.3% |
| FY2018 | Dec 31, 2018 | $19.65B | +4.6% |
| FY2017 | Dec 31, 2017 | $18.78B | -0.3% |
| FY2016 | Dec 31, 2016 | $18.83B | +8.0% |
| FY2015 | Dec 31, 2015 | $17.44B | +11.5% |
| FY2014 | Dec 31, 2014 | $15.64B | +2.0% |
| FY2013 | Dec 31, 2013 | $15.33B | +9.0% |
| FY2012 | Dec 31, 2012 | $14.07B | +9.3% |
| FY2011 | Dec 31, 2011 | $12.87B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.58B | +17.0% |
| Q2 FY2026 | Jun 30, 2026 | $7.24B | +17.4% |
| Q1 FY2026 | Mar 31, 2026 | $5.87B | +13.4% |
| Q4 FY2025 | Dec 31, 2025 | $6.89B | +15.3% |
| Q3 FY2025 | Sep 30, 2025 | $6.48B | +24.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.17B | +19.7% |
| Q1 FY2025 | Mar 31, 2025 | $5.18B | +22.0% |
| Q4 FY2024 | Dec 31, 2024 | $5.97B | +17.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.19B | +1.9% |
| Q2 FY2024 | Jun 30, 2024 | $5.15B | -0.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.25B | -3.1% |
| Q4 FY2023 | Dec 31, 2023 | $5.08B | -0.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.10B | +0.7% |
| Q2 FY2023 | Jun 30, 2023 | $5.17B | +1.8% |
| Q1 FY2023 | Mar 31, 2023 | $4.39B | -6.2% |
| Q4 FY2022 | Dec 31, 2022 | $5.09B | -0.7% |
| Q3 FY2022 | Sep 30, 2022 | $5.06B | +14.8% |
| Q2 FY2022 | Jun 30, 2022 | $5.08B | +7.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.68B | +2.9% |
| Q4 FY2021 | Dec 31, 2021 | $5.13B | +16.0% |
| Q1 FY2021 | Mar 31, 2021 | $4.41B | +0.7% |
| Q4 FY2020 | Dec 31, 2020 | $4.74B | +3.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.54B | +7.4% |
| Q2 FY2020 | Jun 30, 2020 | $4.42B | -9.9% |
| Q1 FY2020 | Mar 31, 2020 | $4.38B | -2.1% |
| Q2 FY2019 | Jun 30, 2019 | $4.56B | -2.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.23B | -3.8% |
| Q4 FY2018 | Dec 31, 2018 | $4.91B | +8.8% |
| Q3 FY2018 | Sep 30, 2018 | $4.47B | +0.2% |
| Q2 FY2018 | Jun 30, 2018 | $4.66B | +2.3% |
| Q1 FY2018 | Mar 31, 2018 | $4.40B | +4.7% |
| Q4 FY2017 | Dec 31, 2017 | $4.51B | -1.9% |
| Q3 FY2017 | Sep 30, 2017 | $4.46B | -0.6% |
| Q2 FY2017 | Jun 30, 2017 | $4.55B | +2.8% |
| Q1 FY2017 | Mar 31, 2017 | $4.20B | – |
| Q4 FY2016 | Dec 31, 2016 | $4.60B | – |
| Q3 FY2016 | Sep 30, 2016 | $4.49B | – |
| Q2 FY2016 | Jun 30, 2016 | $4.42B | – |
See a number that looks wrong?